FDA Approves Dato-DXd for Advanced HR-Positive, HER2-Negative Breast Cancer

FDA Approves New Therapies For NSCLC and SCLC

On December 4, 2024, the FDA announced two significant approvals in lung cancer treatment, including zenocutuzumab-zbco for non-small cell lung cancer (NSCLC) and durvalumab for limited-stage small cell lung cancer (SCLC), marking significant advances in the fight...